易明医药(002826) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥160,858,368.84, a decrease of 0.62% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,173,230.85, down 77.84% year-on-year, while the year-to-date net profit reached ¥41,819,396.00, an increase of 75.06%[2] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥3,971,633.85, a significant increase of 337.92% year-on-year[2] - Total operating revenue for Q3 2024 was CNY 512,843,177.87, a decrease of 4.3% compared to CNY 538,300,734.55 in Q3 2023[19] - Net profit for Q3 2024 reached CNY 42,620,637.91, an increase of 74.8% compared to CNY 24,399,796.33 in Q3 2023[20] - The total comprehensive income for the third quarter was CNY 42,074,848.77, compared to CNY 25,440,081.08 in the previous year, representing a year-over-year increase of approximately 65.4%[21] Assets and Liabilities - The total assets as of September 30, 2024, amounted to ¥953,484,680.54, reflecting a 2.77% increase from the end of the previous year[3] - The company's total assets increased to CNY 953,484,680.54, up from CNY 927,743,602.85 at the end of Q3 2023[19] - The total liabilities rose to CNY 214,723,415.47, compared to CNY 177,684,381.37 in the previous year, indicating an increase of 21%[19] - The company's equity attributable to shareholders decreased to CNY 732,918,567.25 from CNY 745,017,765.57 in the previous year[19] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥113,837,202.53, an increase of 45.75% compared to the same period last year[2] - Cash flow from operating activities generated a net amount of CNY 113,837,202.53, compared to CNY 78,105,720.88 in the previous year, reflecting an increase of 45.5%[23] - Cash inflow from operating activities totaled CNY 611,482,717.11, while cash outflow was CNY 497,645,514.58, resulting in a positive cash flow from operations[23] - The company reported cash and cash equivalents at the end of the period amounting to CNY 227,892,039.74, an increase from CNY 182,588,913.27 at the end of the previous year[23] - The company experienced a foreign exchange impact on cash and cash equivalents amounting to -CNY 88,283.85 during the quarter[23] Expenses - The basic earnings per share for Q3 2024 was ¥0.01, representing an 80.00% decrease compared to the same period last year[3] - The weighted average return on equity for Q3 2024 was 0.30%, down 1.00% from the previous year[3] - The company's sales expenses increased by 37.13% to ¥258,307,479.95 for the year-to-date period compared to the same period last year[7] - The income tax expense increased by 47.05% year-on-year, corresponding to the increase in profit for the period[8] - Research and development expenses for Q3 2024 were CNY 12,082,095.39, slightly higher than CNY 11,672,853.41 in Q3 2023[20] Shareholder Actions - The total number of ordinary shareholders at the end of the reporting period was 18,743[9] - The company repurchased a total of 7,203,800 shares, accounting for 3.7780% of the total share capital, with a total repurchase amount of RMB 50,000,572.63[11] - The company plans to use its own funds to repurchase shares for an amount not less than RMB 50 million and not exceeding RMB 100 million[11] - The company approved a share repurchase agreement for Pier 88 Health Limited, with a total repurchase price of $6,491,178.08[12] Inventory and Receivables - The company's inventory decreased by 32.76% to ¥39,648,652.02 compared to the beginning of the year[7] - Accounts receivable increased by RMB 57,263,900 compared to the beginning of the period, mainly due to uncollected payments for third-party cooperative products[8] - The company’s accounts receivable increased to ¥86,417,880.63 from ¥29,154,026.98, showing a growth of approximately 196%[17] - The company's inventory decreased to ¥39,648,652.02 from ¥58,968,753.01, reflecting a reduction of about 33%[17] Investment Activities - The net cash flow from investing activities decreased by 50.01% year-on-year, amounting to RMB -168,069,784.05[8] - The company’s trading financial assets amounted to ¥160,000,000.00, indicating a new investment strategy[17] - The company has a total of ¥36,000,000 in entrusted financial management, with no overdue amounts reported[13][15] - The company plans to continue its entrusted financial management strategy, indicating ongoing investment activities[15] - The company is exploring future financial management plans, indicating a proactive approach to investment strategies[15] Legal Matters - The company successfully dismissed all litigation requests from the plaintiff in a recent court ruling, reducing potential legal liabilities[12] Audit Status - The third quarter report was not audited, indicating that the figures presented are subject to further verification[24]